MINYANVILLE ORIGINAL It’s back to work and the catalyst calendar is filling up for drug and biotech investors. There are some key dates to circle this week and for the weeks ahead as companies seek approval for new treatments and test experimental therapies.
Here are some highlights for the month. Some dates are subject to change.
(SLXP) expects word from the FDA on approval of the drug crofelemer to treat diarrhea associated with HIV therapies. The agency originally planned to rule on the drug in June, but extended the decision date. In July, regulators shot down Salix’s bid to expand use of the drug Relistor for opioid-induced constipation. Shares of Salix are down 8% this year.
(NVS) faces a panel of expert advisers
to the FDA that will consider the tobramycin inhaled drug for cystic fibrosis patients who suffer a bacteria infection. The big drug maker likely faces some tough questions on the effectiveness of the treatment following an FDA staff review
(PPHM) will announce data from a mid-stage study of its cancer drug bavituximab at a medical meeting. While the drug is being tested for multiple cancers, the late-breaking oral presentation will show results for a trial of the treatment as a secondary option for lung cancer. There’s been a lot of speculation about the drug, leading to considerable volatility in the stock. The shares traded as low as $.40 earlier this year, but have come roaring back, trading at $2.75 each in Tuesday morning trading.
(NAVB) expects to hear whether the FDA will approve Lymphoseek, a radioactive tracing agent for lymph node imaging in cancer patients. The FDA was expected to make a decision in April on the product, but needed more time to assess Navidea’s application. The company said
the delay didn’t appear to be related to concerns about the product’s safety or effectiveness. Navidea was known as Neoprobe until it changed its name in January. The company rebranded itself after selling its medical device business last year.
(CRTX) will face an FDA panel as the company seeks approval of its drug lixivaptan for a metabolic condition that leaves patients short of salt. Cornerstone acquired the drug by taking over Cardiokine earlier this year. Cornerstone shares are up 20% this year.
(REGN) expects to hear from the FDA on a possible expansion of the company’s drug Eylea to treat a condition known as central retinal vein occlusion
. Eylea was approved last year to treat age-related macular degeneration, a leading cause of blindness in the elderly.
No positions in stocks mentioned.
The information on this website solely reflects the analysis of or opinion about the performance of securities and financial markets by the writers whose articles appear on the site. The views expressed by the writers are not necessarily the views of Minyanville Media, Inc. or members of its management. Nothing contained on the website is intended to constitute a recommendation or advice addressed to an individual investor or category of investors to purchase, sell or hold any security, or to take any action with respect to the prospective movement of the securities markets or to solicit the purchase or sale of any security. Any investment decisions must be made by the reader either individually or in consultation with his or her investment professional. Minyanville writers and staff may trade or hold positions in securities that are discussed in articles appearing on the website. Writers of articles are required to disclose whether they have a position in any stock or fund discussed in an article, but are not permitted to disclose the size or direction of the position. Nothing on this website is intended to solicit business of any kind for a writer's business or fund. Minyanville management and staff as well as contributing writers will not respond to emails or other communications requesting investment advice.
Copyright 2011 Minyanville Media, Inc. All Rights Reserved.